Nextera AS
PrivateLast Round
Grant
Nov 21, 2025
Total Funding Raised
$1.12M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Nextera AS is a biotechnology company that develops precision drug candidates for the treatment of cancer, autoimmune diseases, and chronic inflammation using its proprietary NextCore protein engineering platform.
Sector
Enterprise Software
Verticals
Vertical SaaS, E-commerce, Logistics Software
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nextera AS Comparables
Compare Nextera AS with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sriggle | 80% | |
| Moonstride | 80% | |
| Toogonet | 79% | |
Nextera AS Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 21, 2025 |
Nextera AS Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Research Council of Norway | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 1, 2026
Monthly visitors increased 34% MoM.
- Jan 21, 2026
Monthly visitors grew 121% MoM.
Nextera AS Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Nextera AS's valuation, stock price, and market status.